Compare Definium Therapeutics Inc. Common Shares (DFTX) vs Snap Inc (SNAP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Definium Therapeutics Inc. Common Shares vs Snap Inc — how do they compare? Definium Therapeutics Inc. Common Shares trades at $35.59 (market cap $4.59B), while Snap Inc trades at $6 (market cap $9.83B). The key difference: Snap Inc is far larger — about 2.1× Definium Therapeutics Inc. Common Shares's market cap, and Definium Therapeutics Inc. Common Shares is trading nearer its 52-week high, Snap Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Definium Therapeutics Inc. Common Shares for 0 Days and Snap Inc for 68 Days on average.
| DFTX | SNAP | |
|---|---|---|
Market Cap | $4.59B | $9.83B |
Volume | 2,103,937 | 28,532,342 |
Sector | Health | Media |
52-Week High | $48.45 | $9.09 |
52-Week Low | $10.68 | $3.93 |
Typical Hold Time | 0 Days | 68 Days |
Enterprise Value | $3.55B | $11.39B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
SNAP trades at $5.81, up 0.17% on the day, with a bullish technical signal from moving averages. The company reported revenue of $5.93B in 2025, with a net loss narrowing to -$460M, improving its profit margin to -7.77%. Recent news highlights Snap's push into enterprise AR glasses with NVIDIA and Salesforce partnerships, driving investor optimism.
The outlook remains cautious as SNAP continues to post losses despite revenue growth. Analyst consensus is a 'Hold' with a $7.78 price target, suggesting modest upside. Key risks include intense competition, regulatory pressures, and the challenge of achieving profitability. The stock's valuation appears stretched with a high EV/EBITDA of 1,149.99.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Definium Therapeutics Inc. Common Shares
Definium Therapeutics develops investigational treatments for psychiatric and neurological disorders. Formerly MindMed, it focuses on clinical-stage therapies based on novel psychoactive compounds.
Read more on DFTX →About Snap Inc
Snap, which refers to itself as a camera company, has one of the most popular social networking apps, Snapchat, in developed regions such as North America and Europe. The firm has approximately 158 million daily active users. Snap generates nearly all of its revenue from advertising with 88% coming from the U.S. The firm is headquartered in Venice, California.
Read more on SNAP →
